NCT00832364

Trial of an Injectable Biologic and U0279 as Combination Therapy for Severe Plaque-Type Psoriasis

Randomized, Controlled Trial of an Injectable Biologic and U0279 as Combination Therapy for Severe Plaque-Type Psoriasis

• Status: Withdrawn
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Stiefel, a GSK Company · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to assess the safety and efficacy of an injectable biologic and U0279 as combination therapy compared to that of an injectable biologic alone for severe plaque-type psoriasis.

Detailed description

The study is being conducted in order to obtain safety and efficacy data for an injectable biologic and U0279 as combination therapy compared to that of an injectable biologic alone for severe plaque-type psoriasis. The subjects will be randomized to either U0279 or placebo after having been on an injectable biologic for 12 weeks previously. The subject will be on study medication for 12 weeks. The subjects must have moderate to severe Psoriasis

Conditions

• Plaque Psoriasis

Interventions

Type	Name	Description
DRUG	Acitretin (also called U0279)	Capsules containing 25 mg U0279 taken once a day.
DRUG	Placebo	Placebo capsules
BIOLOGICAL	Etanercept	Injectable Biologic

Timeline

• Start date: 2009-10-01
• Primary completion: 2010-03-01
• Completion: 2010-04-01
• First posted: 2009-01-30
• Last updated: 2015-04-21

Locations

3 sites across 1 country: United States